Philadelphia area based XyloCor is developing a gene therapy with the goal of helping to revascularize the heart for refractory angina patients
CEO Al Gianchetti explains that the company recently released final results from a phase 1/2 clinical trial and how XyloCor is set to begin a new study utilizing a catheter system that does not require open heart surgery for delivery.